Paulina Wojnarowicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paulina Wojnarowicz has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Christopher G. Thomson
Pharmaron U.K., Integrated Drug Discovery Services, Pharmaron UK Ltd., Hoddesdon, United Kingdom
26 shared publications - Eric S. Lightcap
HiberCell, Inc., Boston, Massachusetts
26 shared publications - Alan C. Rigby
HiberCell, Inc., Boston, Massachusetts
25 shared publications - Baozhong Li
Pharmaron U.K., Integrated Drug Discovery Services, Pharmaron UK Ltd., Hoddesdon, United Kingdom
25 shared publications - Bradley S. Sherborne
Pharmaron U.K., Integrated Drug Discovery Services, Pharmaron UK Ltd., Hoddesdon, United Kingdom
25 shared publications - Crissy Dudgeon
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
25 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Chemical structures of proposed type 1 and type 2 GCN2-targeting agents
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Chemical structures of proposed type 1 and type 2 GCN2-targeting agents
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
In vivo tumor growth inhibition and plasma concentration of compounds
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
In vivo tumor growth inhibition and plasma concentration of compounds
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Western blot analyses for GCN2/ISR pathway proteins in MOLM-16 cells treated with GCN2-targeting agents in combination with halofuginone
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Western blot analyses for GCN2/ISR pathway proteins in MOLM-16 cells treated with GCN2-targeting agents in combination with halofuginone
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Data from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
General control nonderepressible 2 (GCN2; EIF2AK4) is a serine–threonine kinase in the integrated stress response signaling pathway that initiates adaptive responses during nutrient stress conditions. Although pharmacologic inhibition of GCN2 under nutrient stress conditions induces apoptosis and inhibits tumor growth, GCN2 inhibition without nutrient stress has been reported to have no effect on tumor growth. By exploring an array of GCN2 inhibitors, we demonstrate that multiple agents in fact activate GCN2 in biochemical and cell-based assays at low concentrations and inhibit GCN2 at higher concentrations. Unexpectedly, it is this activation, and not inhibition, of the GCN2 pathway that is associated with decreased viability in vitro and tumor growth inhibition in vivo across multiple models. Knockdown and knockout experiments show that activation of the integrated stress response by GCN2-targeting agents is dependent on GCN2. ISRIB, a modulator of eIF2B, ablates the viability effect, demonstrating the dependence on translation initiation. Activating doses result in the induction of cleaved caspase 3 and cleaved PARP. In contrast, a nonactivating GCN2-targeting agent does not affect viability. These results provide a clearer understanding of the challenges and opportunities for the clinical development of compounds targeting GCN2.
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
General control nonderepressible 2 (GCN2; EIF2AK4) is a serine–threonine kinase in the integrated stress response signaling pathway that initiates adaptive responses during nutrient stress conditions. Although pharmacologic inhibition of GCN2 under nutrient stress conditions induces apoptosis and inhibits tumor growth, GCN2 inhibition without nutrient stress has been reported to have no effect on tumor growth. By exploring an array of GCN2 inhibitors, we demonstrate that multiple agents in fact activate GCN2 in biochemical and cell-based assays at low concentrations and inhibit GCN2 at higher concentrations. Unexpectedly, it is this activation, and not inhibition, of the GCN2 pathway that is associated with decreased viability in vitro and tumor growth inhibition in vivo across multiple models. Knockdown and knockout experiments show that activation of the integrated stress response by GCN2-targeting agents is dependent on GCN2. ISRIB, a modulator of eIF2B, ablates the viability effect, demonstrating the dependence on translation initiation. Activating doses result in the induction of cleaved caspase 3 and cleaved PARP. In contrast, a nonactivating GCN2-targeting agent does not affect viability. These results provide a clearer understanding of the challenges and opportunities for the clinical development of compounds targeting GCN2.
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
HC-7366 viability activity is GCN2 dependent
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
HC-7366 viability activity is GCN2 dependent
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Biochemical inhibition of GCN2 kinase activity of GCN2-targeting agents
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Biochemical inhibition of GCN2 kinase activity of GCN2-targeting agents
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
ScanMAX kinase assay panel results of GCN2-targeting agents
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
ScanMAX kinase assay panel results of GCN2-targeting agents
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
GCN2-targeting agents impact viability as inhibitors in the presence of amino acid deprivation caused by asparaginase, but not halofuginone
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
GCN2-targeting agents impact viability as inhibitors in the presence of amino acid deprivation caused by asparaginase, but not halofuginone
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S16 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Effects of HC-7366 on ISR markers in vivo in FaDu and LoVo models
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S16 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Effects of HC-7366 on ISR markers in vivo in FaDu and LoVo models
- Open Access
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Free fraction of compounds from protein binding assay
- 2 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from In Vivo Tumor Growth Control by General Control Nonderepressible 2–Targeting Agents Results from Kinase Activation
Free fraction of compounds from protein binding assay